GCGR antagonism has been proposed as a pharmacological approach to treat T1D or T2D, including the use of small molecule antagonists, monoclonal antibodies (mAb) against GCGR, and antisense oligonucleotides that reduce expression of the receptor (70–73). Here, GCGR is linked to type 2 diabetes mellitus.